Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report

Area of Science:

• Oncology
• Medical Case Reports
• Pharmacology

Background:

• Ewing's sarcoma family of tumors (ESFT) are rare malignancies.
• Standard treatments include VAC/IE chemotherapy, with limited options for refractory disease.
• Novel therapeutic agents are needed for advanced ESFT.

Purpose of the Study:

• To report a case of metastatic extraskeletal Ewing's sarcoma treated with trabectedin.
• To evaluate the efficacy and tolerability of trabectedin in a pre-treated patient.
• To highlight trabectedin as a potential alternative treatment for ESFT.

Main Methods:

• A 69-year-old female patient with metastatic extraskeletal Ewing's sarcoma was treated.
• Initial treatment with vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (VAC/IE) showed inadequate response.
• Subsequent treatment with gemcitabine and dacarbazine failed, followed by trabectedin therapy.

Main Results:

• Trabectedin treatment resulted in 18 months of progression-free survival.
• The patient achieved disease stabilization with trabectedin.
• Trabectedin demonstrated a favorable tolerability profile.

Conclusions:

• Trabectedin represents a viable alternative treatment for patients with pre-treated, metastatic ESFT.
• Further research is needed to determine optimal use of trabectedin (monotherapy vs. combination) and identify patient subgroups who benefit most.